Halozyme Therapeutics | HALO - Sales Revenues

Stock Price
81.23
Daily Change
2.81 3.58%
Monthly
8.15%
Yearly
42.26%
Q1 Forecast
69.50

Halozyme Therapeutics reported $354M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amarin USD 49.67M 23.07M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Baxter International USD 2.84B 30M Sep/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
MannKind USD 82.13M 5.6M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
United Therapeutics USD 799.5M 900K Sep/2025